AR072804A1 - Conjugados derivados de antraciclina,proceso para su preparacion,composiciones farmaceuticas que los contienen y su uso como agentes antitumorales. - Google Patents
Conjugados derivados de antraciclina,proceso para su preparacion,composiciones farmaceuticas que los contienen y su uso como agentes antitumorales.Info
- Publication number
- AR072804A1 AR072804A1 ARP090102664A ARP090102664A AR072804A1 AR 072804 A1 AR072804 A1 AR 072804A1 AR P090102664 A ARP090102664 A AR P090102664A AR P090102664 A ARP090102664 A AR P090102664A AR 072804 A1 AR072804 A1 AR 072804A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibody
- ant
- binding
- formula
- anthracycline derivative
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8094408P | 2008-07-15 | 2008-07-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR072804A1 true AR072804A1 (es) | 2010-09-22 |
Family
ID=41404334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090102664A AR072804A1 (es) | 2008-07-15 | 2009-07-14 | Conjugados derivados de antraciclina,proceso para su preparacion,composiciones farmaceuticas que los contienen y su uso como agentes antitumorales. |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US8900589B2 (enExample) |
| EP (1) | EP2303332B1 (enExample) |
| JP (2) | JP6067222B2 (enExample) |
| KR (1) | KR101667062B1 (enExample) |
| CN (1) | CN102159248B (enExample) |
| AR (1) | AR072804A1 (enExample) |
| AU (1) | AU2009270988A1 (enExample) |
| BR (1) | BRPI0910810A2 (enExample) |
| CA (1) | CA2727915C (enExample) |
| ES (1) | ES2532635T3 (enExample) |
| IL (1) | IL210003A0 (enExample) |
| MX (1) | MX2011000509A (enExample) |
| PE (1) | PE20110571A1 (enExample) |
| RU (1) | RU2523419C2 (enExample) |
| SG (1) | SG192517A1 (enExample) |
| TW (1) | TWI461428B (enExample) |
| WO (1) | WO2010009124A2 (enExample) |
| ZA (1) | ZA201009122B (enExample) |
Families Citing this family (115)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6136311A (en) | 1996-05-06 | 2000-10-24 | Cornell Research Foundation, Inc. | Treatment and diagnosis of cancer |
| ATE509033T1 (de) | 2006-03-20 | 2011-05-15 | Univ California | Manipulierte anti-prostatastammzellenantigen (psca)-antikörper für krebs-targeting |
| US8940298B2 (en) * | 2007-09-04 | 2015-01-27 | The Regents Of The University Of California | High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection |
| WO2009046294A2 (en) * | 2007-10-03 | 2009-04-09 | Cornell University | Treatment of proliferative disorders using antibodies to psma |
| EP2240495B1 (en) * | 2008-02-01 | 2015-07-15 | Genentech, Inc. | Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods |
| AU2009270988A1 (en) * | 2008-07-15 | 2010-01-21 | Genentech, Inc. | Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds |
| US20100069616A1 (en) * | 2008-08-06 | 2010-03-18 | The Regents Of The University Of California | Engineered antibody-nanoparticle conjugates |
| JP5906090B2 (ja) * | 2009-02-17 | 2016-04-20 | コーネル・リサーチ・ファンデーション・インコーポレイテッドＣｏｒｎｅｌｌ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ， Ｉｎｃｏｒｐｏｒａｔｅｄ | 癌の診断のための方法およびキットならびに治療価の推定 |
| CA3040276A1 (en) | 2009-12-02 | 2011-06-09 | Imaginab, Inc. | J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use |
| AU2011221226A1 (en) | 2010-02-23 | 2012-08-16 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| WO2011109308A1 (en) * | 2010-03-02 | 2011-09-09 | Seattle Genetics, Inc. | Methods for screening antibodies |
| LT2544719T (lt) | 2010-03-12 | 2019-10-25 | Debiopharm Int Sa | Cd37 surišančios molekulės, ir jų imunokonjugatai |
| WO2012019024A2 (en) | 2010-08-04 | 2012-02-09 | Immunogen, Inc. | Her3-binding molecules and immunoconjugates thereof |
| CA2815277A1 (en) | 2010-10-29 | 2012-05-03 | Immunogen, Inc. | Novel egfr-binding molecules and immunoconjugates thereof |
| JP5828902B2 (ja) | 2010-10-29 | 2015-12-09 | イミュノジェン， インコーポレイテッド | 非拮抗性ｅｇｆｒ結合分子およびその免疫複合体 |
| EP2646456B1 (en) | 2010-12-02 | 2015-01-21 | Nerviano Medical Sciences S.r.l. | Process for the preparation of morpholinyl anthracycline derivatives |
| AU2011349443B2 (en) | 2010-12-20 | 2015-12-24 | Genentech, Inc. | Anti-mesothelin antibodies and immunoconjugates |
| AU2012236210B2 (en) | 2011-04-01 | 2016-02-04 | Immunogen, Inc. | CD37-binding molecules and immunoconjugates thereof |
| EP2592103A1 (en) | 2011-11-08 | 2013-05-15 | Adriacell S.p.A. | Polymer aldehyde derivatives |
| JP2014533954A (ja) | 2011-11-21 | 2014-12-18 | イミュノジェン， インコーポレイテッド | Ｅｇｆｒ抗体細胞傷害性薬物複合体による、ｅｇｆｒ療法に耐性である腫瘍の治療方法 |
| BR112014013526A8 (pt) * | 2011-12-05 | 2017-06-13 | Igenica Biotherapeutics Inc | conjugados de anticorpo-fármaco e compostos, composições e métodos relacionados |
| AU2013209512B2 (en) | 2012-01-20 | 2017-08-03 | I2 Pharmaceuticals, Inc. | Surrobody cojugates |
| CA2866699A1 (en) * | 2012-03-09 | 2013-09-12 | Ucl Business Plc | Chemical modification of antibodies |
| AR090549A1 (es) | 2012-03-30 | 2014-11-19 | Genentech Inc | Anticuerpos anti-lgr5 e inmunoconjugados |
| ES2686683T3 (es) | 2012-04-05 | 2018-10-19 | Nerviano Medical Sciences S.R.L. | Derivados de tieno-indol funcionalizados |
| ES2929759T3 (es) | 2012-04-05 | 2022-12-01 | Nerviano Medical Sciences Srl | Nuevos agentes alquilantes |
| KR20150006000A (ko) | 2012-05-01 | 2015-01-15 | 제넨테크, 인크. | 항-pmel17 항체 및 면역접합체 |
| US9078926B2 (en) | 2012-05-07 | 2015-07-14 | Nitto Denko Corporation | Polymer conjugates with a linker |
| CN104640572B (zh) | 2012-05-15 | 2018-04-27 | 索伦托医疗有限公司 | 药物偶联物，偶联方法，及其用途 |
| PE20150025A1 (es) | 2012-05-21 | 2015-02-09 | Genentech Inc | Anticuerpos e inmunoconjugados contra ly6e y metodos de uso |
| CA2874904A1 (en) * | 2012-07-09 | 2014-01-16 | Genentech, Inc. | Immunoconjugates comprising anti-cd22 antibodies |
| AU2013288932A1 (en) | 2012-07-09 | 2014-12-11 | Genentech, Inc. | Immunoconjugates comprising anti - CD79b antibodies |
| WO2014022680A1 (en) * | 2012-08-02 | 2014-02-06 | Genentech, Inc. | Anti-etbr antibodies and immunoconjugates |
| BR112015002193A2 (pt) | 2012-08-02 | 2017-07-04 | Genentech Inc | anticorpos anti-etbr e imunoconjugados |
| WO2014067960A2 (en) | 2012-10-30 | 2014-05-08 | Nerviano Medical Sciences S.R.L. | Functionalized 9-bromo-camptothecin derivatives |
| EA201591465A1 (ru) * | 2013-02-08 | 2015-12-30 | АйАрЭм ЭлЭлСи | Специфичные участки для модификации антител для получения иммуноконъюгатов |
| MX2015010777A (es) | 2013-03-14 | 2016-04-25 | Genentech Inc | Anticuerpos e inmunoconjugados anti-b7-h4. |
| US9562099B2 (en) | 2013-03-14 | 2017-02-07 | Genentech, Inc. | Anti-B7-H4 antibodies and immunoconjugates |
| EP2777714A1 (en) | 2013-03-15 | 2014-09-17 | NBE-Therapeutics LLC | Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme |
| CN105164138B (zh) * | 2013-04-29 | 2017-11-07 | 内尔维阿诺医学科学有限公司 | 新吗啉基蒽环类抗生素衍生物 |
| GB201309807D0 (en) | 2013-05-31 | 2013-07-17 | Pharma Mar Sau | Antibody drug conjugates |
| WO2014197866A1 (en) | 2013-06-06 | 2014-12-11 | Igenica Biotherapeutics, Inc. | Modified antibodies and related compounds, compositions, and methods of use |
| TWI725931B (zh) | 2013-06-24 | 2021-05-01 | 美商建南德克公司 | 抗ｆｃｒｈ５抗體 |
| AU2014293013A1 (en) | 2013-07-26 | 2016-03-17 | Race Oncology Ltd. | Combinatorial methods to improve the therapeutic benefit of bisantrene |
| CN105764526B (zh) | 2013-08-26 | 2020-12-15 | 生物技术研发公司 | 编码抗唾液酸化路易斯a抗原的人抗体的核酸 |
| BR112016004450A2 (pt) | 2013-09-17 | 2017-10-17 | Genentech Inc | métodos para tratar uma doença, para aumentar a eficácia de um tratamento, para adiar e/ou prevenir desenvolvimento da reincidência e/ou resistência de uma doença, para aumentar a sensibilidade a um inibidor, para estender o período de sensibilidade a um inibidor e para estender a duração de resposta a um inibidor |
| US10266547B2 (en) | 2013-09-25 | 2019-04-23 | Nerviano Medical Sciences S.R.L. | Thieno[2,3-e]indole derivatives as new antitumor agents |
| AU2014337317A1 (en) | 2013-10-15 | 2016-09-15 | Sorrento Therapeutics Inc. | Drug-conjugates with a targeting molecule and two different drugs |
| KR20160068963A (ko) | 2013-10-21 | 2016-06-15 | 제넨테크, 인크. | 항-Ly6E 항체 및 사용 방법 |
| AR098743A1 (es) | 2013-12-13 | 2016-06-08 | Genentech Inc | Anticuerpos e inmunoconjugados anti-cd33 |
| BR112016012410A2 (pt) | 2013-12-16 | 2017-09-26 | Genentech Inc | conjugado de droga e anticorpo, composto conjugado de droga e anticorpo, composto não-peptídico, método de tratamento de doenças em seres humanos e composição farmacêutica |
| HUE050159T2 (hu) | 2013-12-17 | 2020-11-30 | Genentech Inc | Anti-CD3 antitestek és alkalmazási eljárások |
| CA2943609A1 (en) | 2014-03-27 | 2015-10-01 | The Brigham And Women's Hospital, Inc. | Metabolically-activated drug conjugates to overcome resistance in cancer therapy |
| JP2017522861A (ja) | 2014-05-22 | 2017-08-17 | ジェネンテック， インコーポレイテッド | 抗ｇｐｃ３抗体及びイムノコンジュゲート |
| US9856324B2 (en) | 2014-06-04 | 2018-01-02 | MabVax Therapeutics, Inc. | Human monoclonal antibodies to ganglioside GD2 |
| AU2015271100B2 (en) | 2014-06-06 | 2020-07-30 | Redwood Bioscience, Inc. | Anti-HER2 antibody-maytansine conjugates and methods of use thereof |
| DK3186284T3 (da) | 2014-08-28 | 2022-05-09 | Bioatla Inc | Betinget aktive kimæriske antigenreceptorer til modificerede t-celler |
| MA40579A (fr) | 2014-09-12 | 2016-03-17 | Genentech Inc | Anticorps anti-cll-1 et immunoconjugués |
| JP2017531620A (ja) | 2014-09-12 | 2017-10-26 | ジェネンテック， インコーポレイテッド | システイン操作抗体及びコンジュゲート |
| TW201625689A (zh) | 2014-09-12 | 2016-07-16 | 建南德克公司 | 抗－ｂ７－ｈ４抗體及免疫結合物 |
| SI3191135T1 (sl) | 2014-09-12 | 2021-01-29 | Genentech, Inc. | Anti-HER2 protitelesa in imunokonjugati |
| US10149913B2 (en) | 2014-09-12 | 2018-12-11 | Genentech, Inc. | Anthracycline disulfide intermediates, antibody-drug conjugates and methods |
| GB201419108D0 (en) * | 2014-10-27 | 2014-12-10 | Glythera Ltd | Materials and methods relating to linkers for use in antibody drug conjugates |
| RU2715902C2 (ru) * | 2014-11-05 | 2020-03-04 | НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. | Функционализированные производные морфолинилантрациклина |
| CA2969689A1 (en) * | 2014-12-03 | 2016-06-09 | Genentech, Inc. | Quaternary amine compounds and antibody-drug conjugates thereof |
| BR122020025870B1 (pt) | 2014-12-23 | 2024-01-09 | Nbe-Therapeutics Ag | Método para a produção de um conjugado de proteína de ligaçãofármaco |
| JP6871858B2 (ja) | 2015-01-28 | 2021-05-19 | ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | 抗体薬物コンジュゲート |
| US20170224835A1 (en) * | 2015-02-06 | 2017-08-10 | Sorrento Therapeutics, Inc. | Antibody Drug Conjugates |
| BR112017026027A2 (pt) | 2015-06-08 | 2018-08-14 | Debiopharm Int Sa | combinações de imunoconjugado anti-cd37 e anticorpo anti-cd20 |
| US10323094B2 (en) | 2015-06-16 | 2019-06-18 | Genentech, Inc. | Humanized and affinity matured antibodies to FcRH5 and methods of use |
| CN108136012B (zh) | 2015-08-07 | 2022-10-04 | 伊麦吉纳博公司 | 靶向分子的抗原结合构建体 |
| JP6890581B2 (ja) | 2015-08-28 | 2021-06-18 | デビオファーム インターナショナル， エス． アー． | Ｃｄ３７の検出のための抗体およびアッセイ |
| AU2016334715B2 (en) | 2015-10-05 | 2023-02-02 | Fredax Ab | Humanized anti PSA (5A10) antibodies |
| MA43354A (fr) | 2015-10-16 | 2018-08-22 | Genentech Inc | Conjugués médicamenteux à pont disulfure encombré |
| TWI660741B (zh) | 2015-11-03 | 2019-06-01 | 財團法人工業技術研究院 | 抗體藥物複合物及其製造方法 |
| PT3380495T (pt) * | 2015-11-24 | 2021-08-19 | Transfert Plus Sec | Compostos peptídicos e conjugados peptídicos para o tratamento de cancro através de quimioterapia mediada por recetores |
| CN107847605B (zh) * | 2015-11-25 | 2021-12-24 | 乐高化学生物科学股份有限公司 | 包含分支接头的抗体-药物缀合物及其相关方法 |
| US11583593B2 (en) | 2016-01-14 | 2023-02-21 | Synthis Therapeutics, Inc. | Antibody-ALK5 inhibitor conjugates and their uses |
| MX390630B (es) * | 2016-01-25 | 2025-03-21 | Regeneron Pharma | Derivados de maitansinoide, conjugados de los mismos y metodos de uso. |
| BR112018068461A2 (pt) | 2016-03-15 | 2019-01-22 | Mersana Therapeutics Inc | conjugado, composição farmacêutica, métodos para preparação de um conjugado e para alívio de um sintoma de um câncer. |
| CN108700598A (zh) | 2016-03-25 | 2018-10-23 | 豪夫迈·罗氏有限公司 | 多路总抗体和抗体缀合的药物量化测定法 |
| EP4656204A3 (en) | 2016-04-15 | 2026-06-03 | BioAtla, Inc. | Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof |
| EP4122958A1 (en) | 2016-05-13 | 2023-01-25 | BioAtla, Inc. | Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof |
| CN109152843A (zh) | 2016-05-20 | 2019-01-04 | 豪夫迈·罗氏有限公司 | Protac抗体缀合物及其使用方法 |
| CN109313200B (zh) | 2016-05-27 | 2022-10-04 | 豪夫迈·罗氏有限公司 | 用于表征位点特异性抗体-药物缀合物的生物分析性方法 |
| WO2017207540A1 (en) | 2016-05-30 | 2017-12-07 | Toxinvent Oü | Antibody-drug-conjugates comprising novel anthracycline-derivatives for cancer treatment |
| WO2018005660A1 (en) | 2016-06-28 | 2018-01-04 | University Of Kentucky Research Foundation | Prostaglandin e synthase inhibitors and methods for utilizing the same |
| US11278629B2 (en) | 2016-11-02 | 2022-03-22 | Debiopharm International, S.A. | Methods for improving anti-CD37 immunoconjugate therapy |
| CA3036983A1 (en) | 2016-11-21 | 2018-05-24 | Cureab Gmbh | Anti-gp73 antibodies and immunoconjugates |
| WO2018103739A1 (zh) * | 2016-12-09 | 2018-06-14 | 凯惠科技发展(上海)有限公司 | 抗体药物偶联物、制备方法、中间体、药物组合物及应用 |
| WO2018147960A1 (en) | 2017-02-08 | 2018-08-16 | Imaginab, Inc. | Extension sequences for diabodies |
| LT3615544T (lt) | 2017-04-27 | 2023-05-10 | Pharma Mar S.A. | Priešnavikiniai junginiai |
| TWI804499B (zh) | 2017-06-23 | 2023-06-11 | 美商維洛斯生物公司 | Ror1抗體免疫接合物 |
| EP3685166A2 (en) | 2017-09-20 | 2020-07-29 | Mersana Therapeutics, Inc. | Compositions and methods for predicting response to napi2b-targeted therapy |
| US11707522B2 (en) | 2017-10-13 | 2023-07-25 | Boehringer Ingelheim International Gmbh | Human antibodies to Tn antigen |
| AU2019277836A1 (en) | 2018-05-30 | 2021-01-21 | Debiopharm International, S.A. | Anti-CD37 immunoconjugate dosing regimens |
| AU2018431586B2 (en) * | 2018-07-09 | 2025-03-20 | Synthis Therapeutics, Inc | Antibody-ALK5 inhibitor conjugates and their uses |
| EP3826625A4 (en) | 2018-07-23 | 2022-08-24 | Magenta Therapeutics, Inc. | USE OF ANTI-CD5 ANTIBODY DRUG CONJUGATE (ADC) IN ALLOGENE CELL THERAPY |
| JP2021534188A (ja) | 2018-08-17 | 2021-12-09 | メルサナ セラピューティクス インコーポレイテッド | ＮａＰｉ２ｂに標的指向されたポリマー抗体−薬物コンジュゲートおよびその使用方法 |
| TWI824043B (zh) | 2018-10-25 | 2023-12-01 | 西班牙商瑪製藥股份有限公司 | 藥物抗體共軛物 |
| EP3976112A1 (en) | 2019-06-03 | 2022-04-06 | Synaffix B.V. | Acetal-based cleavable linkers |
| EP3980423A1 (en) | 2019-06-10 | 2022-04-13 | Sutro Biopharma, Inc. | 5h-pyrrolo[3,2-d]pyrimidine-2,4-diamino compounds and antibody conjugates thereof |
| EP3980080A1 (en) * | 2019-06-10 | 2022-04-13 | Sutro Biopharma, Inc. | Immunomodulator antibody drug conjugates and uses thereof |
| GB201908886D0 (en) * | 2019-06-20 | 2019-08-07 | Almac Discovery Ltd | Anthracycline derivatives |
| IL299860A (en) | 2020-07-21 | 2023-03-01 | Genentech Inc | Antibody-conjugated chemical factors for the discharge of BRM and their methods |
| WO2022122709A1 (en) | 2020-12-07 | 2022-06-16 | Sotio Biotech A.S. | Antibody-drug conjugates based on humanized cldn18.2 antibodies |
| KR20230124037A (ko) * | 2020-12-23 | 2023-08-24 | 소티오 바이오테크 에이.에스. | 종양 특이적 claudin 18.2 항체-약물 접합체 |
| JP7731066B2 (ja) * | 2020-12-25 | 2025-08-29 | パナソニックＩｐマネジメント株式会社 | 作物収量向上剤、及び、作物収量向上方法 |
| CN112924665B (zh) * | 2021-02-19 | 2023-10-03 | 山东莱博生物科技有限公司 | 一种抗体辣根过氧化物酶标记物及其制备与应用 |
| JP2024510435A (ja) | 2021-03-18 | 2024-03-07 | シージェン インコーポレイテッド | 生体活性化合物の内部移行複合体からの選択的薬物放出 |
| EP4180061A1 (en) | 2021-11-10 | 2023-05-17 | Nerviano Medical Sciences S.r.l. | Anthracycline derivative linker reagents, antibody-drug conjugates and methods |
| AR128331A1 (es) | 2022-01-26 | 2024-04-17 | Genentech Inc | Inductores químicos de degradación conjugados con anticuerpos y métodos de estos |
| AR128330A1 (es) | 2022-01-26 | 2024-04-17 | Genentech Inc | Inductores químicos de degradación conjugados con anticuerpo y métodos de estos |
| WO2025032254A1 (en) * | 2023-08-10 | 2025-02-13 | Astrazeneca Ab | Anthracycline derivatives and conjugates and uses thereof |
| WO2025168481A1 (en) | 2024-02-05 | 2025-08-14 | Nerviano Medical Sciences S.R.L. | Imino-anthracycline derivatives and methods |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US5162512A (en) | 1982-03-09 | 1992-11-10 | Cytogen Corporation | Amine derivatives of anthracycline antibodies |
| US4826964A (en) * | 1982-07-20 | 1989-05-02 | Sri International | Bridged oxygen analogs of daunorubcin and doxorubicin |
| GB2172594B (en) * | 1985-03-22 | 1988-06-08 | Erba Farmitalia | New morpholino derivatives of daunorubicin and doxorubicin |
| US5583024A (en) | 1985-12-02 | 1996-12-10 | The Regents Of The University Of California | Recombinant expression of Coleoptera luciferase |
| IL89220A (en) | 1988-02-11 | 1994-02-27 | Bristol Myers Squibb Co | Anthracycline immunoconjugates, their production and pharmaceutical compositions containing them |
| CA2016584C (en) * | 1989-05-17 | 1999-06-29 | Robert S. Greenfield | Anthracycline conjugates having a novel linker and methods for their production |
| US5304687A (en) * | 1989-12-19 | 1994-04-19 | Farmitalia Carlo Erba S.R.L. | Morpholinyl derivatives of doxorubicin and process for their preparation |
| GB9017024D0 (en) | 1990-08-03 | 1990-09-19 | Erba Carlo Spa | New linker for bioactive agents |
| GB9019933D0 (en) | 1990-09-12 | 1990-10-24 | Erba Carlo Spa | 13-dihydro-3'-(2-alkoxy-4-morphlinyl)anthracyclines |
| CA2048089A1 (en) | 1990-09-17 | 1992-03-18 | Wolfgang A. Wrasidlo | Chemical conjugation of morpholino anthracyclines to antibodies |
| US5776458A (en) * | 1990-12-05 | 1998-07-07 | Pharmacia & Upjohn S.P.A. | Anthracycline-conjugates |
| GB9026491D0 (en) * | 1990-12-05 | 1991-01-23 | Erba Carlo Spa | Anthracycline-conjugates |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US5362852A (en) | 1991-09-27 | 1994-11-08 | Pfizer Inc. | Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties |
| AU4025193A (en) | 1992-04-08 | 1993-11-18 | Cetus Oncology Corporation | Humanized C-erbB-2 specific antibodies |
| PT616812E (pt) | 1993-03-24 | 2000-04-28 | Berlex Biosciences | Combinacao de compostos anti-hormonais e moleculas de ligacao no tratamento do cancro |
| GB2296495B (en) | 1994-12-23 | 1998-04-15 | Erba Carlo Spa | Anthracycline derivatives |
| JPH08336393A (ja) | 1995-04-13 | 1996-12-24 | Mitsubishi Chem Corp | 光学活性なγ−置換−β−ヒドロキシ酪酸エステルの製造法 |
| CA2226575C (en) | 1995-07-27 | 2011-10-18 | Genentech, Inc. | Stabile isotonic lyophilized protein formulation |
| US5843903A (en) * | 1995-11-27 | 1998-12-01 | The Administrators Of The Tulane Educational Fund | Targeted cytotoxic anthracycline analogs |
| GB2315067B (en) | 1996-07-11 | 2000-02-16 | Pharmacia Spa | Morpholinyl anthracycline derivatives |
| US6602677B1 (en) | 1997-09-19 | 2003-08-05 | Promega Corporation | Thermostable luciferases and methods of production |
| JP4689781B2 (ja) | 1998-09-03 | 2011-05-25 | 独立行政法人科学技術振興機構 | アミノ酸輸送蛋白及びその遺伝子 |
| NZ502058A (en) | 1999-12-23 | 2003-11-28 | Ovita Ltd | Isolated mutated nucleic acid molecule for regulation of ovulation rate |
| AU767394C (en) * | 1999-12-29 | 2005-04-21 | Immunogen, Inc. | Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use |
| EP1474528A4 (en) | 2000-10-13 | 2006-06-14 | Protein Design Labs Inc | METHODS OF DIAGNOSIS OF PROSTATE CANCER, COMPOSITIONS AND METHODS OF EXAMINING PROSTATE CANCER MODULATORS |
| EP1357828A2 (en) | 2001-01-12 | 2003-11-05 | University of Medicine and Dentistry of New Jersey | Bone morphogenetic protein-2 in the treatment and diagnosis of cancer |
| EP1425302A2 (en) | 2001-01-24 | 2004-06-09 | Protein Design Labs | Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer |
| WO2002064780A1 (en) | 2001-02-12 | 2002-08-22 | Bionomics Limited | Dna sequences for human tumour suppressor genes |
| EP1243276A1 (en) * | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
| US20040236091A1 (en) | 2001-03-28 | 2004-11-25 | Chicz Roman M. | Translational profiling |
| CA2444691A1 (en) | 2001-04-18 | 2002-10-31 | Protein Design Labs, Inc. | Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer |
| WO2002098358A2 (en) | 2001-06-04 | 2002-12-12 | Eos Biotechnology, Inc. | Methods of diagnosis and treatment of androgen-dependent prostate cancer, prostate cancer undergoing androgen-withdrawal, and androgen-independent prostate cancer |
| WO2002099083A2 (en) | 2001-06-05 | 2002-12-12 | Exelixis, Inc. | Gfats as modifiers of the p53 pathway and methods of use |
| EP1402058A4 (en) | 2001-06-05 | 2006-02-01 | Exelixis Inc | DGKS AS P53 PATH MODIFICATORS AND METHOD OF USE |
| MXPA03011979A (es) | 2001-06-18 | 2005-04-08 | Eos Biotechnology Inc | Metodos de diagnostico de cancer de ovario composiciones y metodos para rastrear moduladores de cancer de ovario. |
| US7803915B2 (en) | 2001-06-20 | 2010-09-28 | Genentech, Inc. | Antibody compositions for the diagnosis and treatment of tumor |
| US20050107595A1 (en) | 2001-06-20 | 2005-05-19 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| US20040076955A1 (en) | 2001-07-03 | 2004-04-22 | Eos Biotechnology, Inc. | Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer |
| AU2002324700A1 (en) | 2001-08-14 | 2003-03-03 | Bayer Ag | Nucleic acid and amino acid sequences involved in pain |
| CA2459219A1 (en) | 2001-09-17 | 2003-03-27 | Protein Design Labs, Inc. | Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer |
| NZ573739A (en) | 2001-09-18 | 2010-07-30 | Genentech Inc | Compositions and methods for the diagnosis and treatment of tumor, particularly colorectal tumor - TAT201 |
| WO2003029421A2 (en) | 2001-10-03 | 2003-04-10 | Origene Technologies, Inc. | Regulated breast cancer genes |
| CN1966725A (zh) | 2001-10-31 | 2007-05-23 | 爱尔康公司 | 骨形态生发蛋白(bmp)、bmp受体和bmp结合蛋白及它们在诊断和治疗青光眼中的用途 |
| WO2003042661A2 (en) | 2001-11-13 | 2003-05-22 | Protein Design Labs, Inc. | Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer |
| US20030134790A1 (en) | 2002-01-11 | 2003-07-17 | University Of Medicine And Dentistry Of New Jersey | Bone Morphogenetic Protein-2 And Bone Morphogenetic Protein-4 In The Treatment And Diagnosis Of Cancer |
| AU2003232453A1 (en) | 2002-05-30 | 2003-12-19 | David K. Bol | Human solute carrier family 7 member 11 (hslc7a11) |
| JP2006501849A (ja) | 2002-10-04 | 2006-01-19 | ヴァン アンデル リサーチ インスティチュート | 腎腫瘍の分子サブ分類および新規診断マーカーの発見 |
| AU2003298786A1 (en) | 2002-11-26 | 2004-06-18 | Protein Design Labs, Inc. | Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators |
| US20050227301A1 (en) | 2003-01-10 | 2005-10-13 | Polgen | Cell cycle progression proteins |
| US20040202666A1 (en) * | 2003-01-24 | 2004-10-14 | Immunomedics, Inc. | Anti-cancer anthracycline drug-antibody conjugates |
| CA2519289A1 (en) | 2003-03-18 | 2004-09-30 | Antonino Suarato | Nemorubicin as radiosensitizer in combination with radiation therapy against tumors |
| MXPA05009849A (es) | 2003-03-18 | 2005-12-06 | Pharmacia Italia Spa | Terapia combinada que comprende nemorubicina y un inhibidor de la ciclooxigenasa-2. |
| KR20060107501A (ko) * | 2003-06-30 | 2006-10-13 | 바이오-테크널러지 제너럴 (이스라엘) 리미티드 | 특이적인 인간 항체 |
| ES2605443T3 (es) | 2003-11-06 | 2017-03-14 | Seattle Genetics, Inc. | Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia |
| NZ551180A (en) | 2004-06-01 | 2009-10-30 | Genentech Inc | Antibody drug conjugates and methods |
| TR201808537T4 (tr) | 2004-09-23 | 2018-07-23 | Genentech Inc | Sistein değiştirilmiş antikorlar ve konjugatlar. |
| US20070060534A1 (en) * | 2005-06-30 | 2007-03-15 | Threshold Pharmaceuticals, Inc. | Anthracycline analogs |
| HUE035853T2 (en) * | 2005-07-18 | 2018-05-28 | Seattle Genetics Inc | Beta-glucuronide-linker-drug conjugates |
| PE20090245A1 (es) | 2007-05-08 | 2009-03-17 | Genentech Inc | Anticuerpos anti-muc16 disenados con cisteina y conjugados de anticuerpos y farmacos |
| EP2240495B1 (en) * | 2008-02-01 | 2015-07-15 | Genentech, Inc. | Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods |
| AU2009270988A1 (en) * | 2008-07-15 | 2010-01-21 | Genentech, Inc. | Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds |
| EP2646456B1 (en) * | 2010-12-02 | 2015-01-21 | Nerviano Medical Sciences S.r.l. | Process for the preparation of morpholinyl anthracycline derivatives |
-
2009
- 2009-07-14 AU AU2009270988A patent/AU2009270988A1/en not_active Abandoned
- 2009-07-14 PE PE2011000027A patent/PE20110571A1/es not_active Application Discontinuation
- 2009-07-14 US US12/502,433 patent/US8900589B2/en active Active
- 2009-07-14 ES ES09790394.2T patent/ES2532635T3/es active Active
- 2009-07-14 MX MX2011000509A patent/MX2011000509A/es active IP Right Grant
- 2009-07-14 BR BRPI0910810A patent/BRPI0910810A2/pt not_active IP Right Cessation
- 2009-07-14 EP EP09790394.2A patent/EP2303332B1/en active Active
- 2009-07-14 CA CA2727915A patent/CA2727915C/en active Active
- 2009-07-14 JP JP2011518840A patent/JP6067222B2/ja not_active Expired - Fee Related
- 2009-07-14 CN CN2009801359822A patent/CN102159248B/zh not_active Expired - Fee Related
- 2009-07-14 WO PCT/US2009/050537 patent/WO2010009124A2/en not_active Ceased
- 2009-07-14 KR KR1020117003368A patent/KR101667062B1/ko not_active Expired - Fee Related
- 2009-07-14 RU RU2011105402/15A patent/RU2523419C2/ru active IP Right Revival
- 2009-07-14 SG SG2013053939A patent/SG192517A1/en unknown
- 2009-07-14 TW TW098123764A patent/TWI461428B/zh not_active IP Right Cessation
- 2009-07-14 AR ARP090102664A patent/AR072804A1/es unknown
-
2010
- 2010-12-15 IL IL210003A patent/IL210003A0/en unknown
- 2010-12-20 ZA ZA2010/09122A patent/ZA201009122B/en unknown
-
2012
- 2012-01-27 US US13/360,212 patent/US8389697B2/en not_active Expired - Fee Related
-
2014
- 2014-10-30 US US14/528,142 patent/US9695240B2/en not_active Expired - Fee Related
-
2015
- 2015-06-03 JP JP2015113517A patent/JP2016006045A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20120130059A1 (en) | 2012-05-24 |
| PE20110571A1 (es) | 2011-08-29 |
| BRPI0910810A2 (pt) | 2019-09-24 |
| CA2727915C (en) | 2016-04-26 |
| AU2009270988A1 (en) | 2010-01-21 |
| CA2727915A1 (en) | 2010-01-21 |
| CN102159248B (zh) | 2013-09-11 |
| ZA201009122B (en) | 2012-03-28 |
| JP2011528360A (ja) | 2011-11-17 |
| HK1157660A1 (en) | 2012-07-06 |
| JP2016006045A (ja) | 2016-01-14 |
| KR101667062B1 (ko) | 2016-10-17 |
| RU2523419C2 (ru) | 2014-07-20 |
| TW201011041A (en) | 2010-03-16 |
| RU2011105402A (ru) | 2012-08-20 |
| ES2532635T3 (es) | 2015-03-30 |
| CN102159248A (zh) | 2011-08-17 |
| US20150051380A1 (en) | 2015-02-19 |
| US8900589B2 (en) | 2014-12-02 |
| US8389697B2 (en) | 2013-03-05 |
| US9695240B2 (en) | 2017-07-04 |
| WO2010009124A2 (en) | 2010-01-21 |
| EP2303332B1 (en) | 2014-12-31 |
| MX2011000509A (es) | 2011-04-05 |
| EP2303332A2 (en) | 2011-04-06 |
| SG192517A1 (en) | 2013-08-30 |
| JP6067222B2 (ja) | 2017-01-25 |
| US20100034837A1 (en) | 2010-02-11 |
| KR20110040922A (ko) | 2011-04-20 |
| TWI461428B (zh) | 2014-11-21 |
| WO2010009124A3 (en) | 2010-12-23 |
| IL210003A0 (en) | 2011-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020551969A1 (en) | Anti-muc1 antibody-drug conjugate | |
| ECSP077310A (es) | Anticuerpos anti-5t4 humanizados y conjugados de anticuerpos anti-5t4/caliqueamicina | |
| RU2016150377A (ru) | Сайт-специфичная конъюгация линкерных лекарственных препаратов с антителами и получаемые в результате adc | |
| HRP20241082T1 (hr) | Konjugati protutijelo-lijek humaniziranog anti-prostata specifičnog membranskog antigena (psma) | |
| JP2011519864A5 (enExample) | ||
| CR10273A (es) | "anticuerpos anti-5t4 y usos de los mismos" | |
| UA114879C2 (uk) | Антитіло до cd38 для лікування раку | |
| FI3283521T3 (fi) | Lääkekonjugaatteja käsittäen vasta-aineita claudiinia 18.2 vastaan | |
| PE20190512A1 (es) | Conjugados de anticuerpo anti-egfr y farmaco | |
| JP2024533356A5 (enExample) | ||
| IL299362A (en) | Antibody-drug conjugates that include anti-H3-B7 antibodies | |
| RU2010148740A (ru) | Высокоэффективные конъюгаты и гидрофильные сшивающие агенты (линкеры) | |
| AR069747A1 (es) | Conjugado anticuerpo monoclonal anti-b7h4- farmaco y metodos de utilizacion | |
| CY1118053T1 (el) | Φαρμακευτικες συνθεσεις με ανθεκτικοτητα σε διαλυτο cea | |
| IL308795A (en) | Anthracycline antibody conjugates | |
| CY1119342T1 (el) | Τριμερης πρωτεϊνη συντηξης οχ40-ανοσοσφαιρινης και μεθοδοι χρησης | |
| MX346912B (es) | Metodos para mejorar terapia con anticuerpos antitumor. | |
| NZ712035A (en) | Pyrrolobenzodiazepines and conjugates thereof | |
| MX350230B (es) | Vacunas anticancer de globo h y relacionadas con adyuvantes de glucolipido novedosos. | |
| WO2010009124A3 (en) | Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds | |
| PE20251072A1 (es) | Conjugados de anticuerpo-farmaco de compuestos antineoplasicos y metodos de uso de los mismos | |
| HRP20210410T1 (hr) | Konjugirana antitijela prema ly75 za liječenje raka | |
| JP2022512401A5 (enExample) | ||
| CO2026004920A2 (es) | Métodos y composiciones para el tratamiento de tumores usando conjugados de anticuerpos y fármacos de camptotecina | |
| CO2022004606A2 (es) | Conjugados de amatoxina y anticuerpo específicos de linfocitos b |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |